Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,585 USD | -0,63% | -0,94% | +12,41% |
15/03 | ATYR PHARMA, INC. : Een koopadvies van RBC Capital Markets | ZM |
14/03 | Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
Omzet 2024 * | 2,62 mln. 2,45 mln. | Omzet 2025 * | 9,26 mln. 8,65 mln. | Marktkapitalisatie | 108 mln. 101 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -63 mln. -58,84 mln. | Nettowinst (verlies) 2025 * | -66 mln. -61,64 mln. | EV/omzet 2024 * | 41,3 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 11,7 x |
K/w-verhouding 2024 * |
-1,61
x | K/w-verhouding 2025 * |
-1,67
x | Werknemers | 58 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,38% |
Recentste transcriptie over aTyr Pharma, Inc.
1 dag | -0,63% | ||
1 week | -0,94% | ||
Lopende maand | -18,72% | ||
1 maand | -17,23% | ||
3 maanden | +0,32% | ||
6 maanden | +28,86% | ||
Lopend jaar | +12,41% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 30-03-16 |
Jill Broadfoot
DFI | Director of Finance/CFO | 63 | 30-07-18 |
Lisa Carey
CTO | Chief Tech/Sci/R&D Officer | - | 01-06-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Schimmel
FOU | Founder | 83 | 08-09-05 |
Tim Coughlin
CHM | Chairman | 57 | 10-04-17 |
John Clarke
BRD | Director/Board Member | 70 | 01-09-05 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 1,585 | -0,63% | 184 506 |
25-04-24 | 1,595 | -0,31% | 306 541 |
24-04-24 | 1,6 | -1,23% | 288 059 |
23-04-24 | 1,62 | -1,22% | 238 347 |
22-04-24 | 1,64 | +2,50% | 293 599 |
uitgestelde koers Nasdaq, 26 april 2024 om 21:06 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+12,41% | 108 mln. | |
+2,01% | 42,59 mld. | |
+8,42% | 40,65 mld. | |
+49,22% | 40,57 mld. | |
-12,36% | 26,77 mld. | |
+8,74% | 24,81 mld. | |
-24,34% | 18,17 mld. | |
+29,14% | 12,05 mld. | |
-2,87% | 11,7 mld. | |
+6,95% | 11,1 mld. |